Amarin and HEXAL in formulation deal

Related tags Denmark

Sweden's Amarin Development has been commissioned by GEA
Farmaceutisk Fabrik, a Danish subsidiary of German pharmaceutical
company HEXAL, to develop a formulation of one of its candidate
compounds.

Sweden's Amarin Development has been commissioned by GEA Farmaceutisk Fabrik, a Danish subsidiary of German pharmaceutical company HEXAL, to develop a formulation of one of its candidate compounds.

The development programme will use Amarin's patented oral technology that regulates the release of drug by diffusion through a membrane which can be adjusted by varying the porosity and thickness. The identity of the specific drug substance is not being divulged, although Amarin did reveal that the licensing agreement covers global distribution rights.

The deal "is good news for Amarin and provides further evidence of our strengthening position within the Scandinavian region, where we have comprehensive development agreements with companies in Sweden, Finland and now Denmark,"​ commented Rick Stewart, chief executive of Amarin.

Related topics Ingredients